Trial Profile
Baseline characteristics of patients with COPD (chronic bronchitis, emphysema) who require LABA and LAMA (both free and fixed combination) for maintenance therapy other than tiotropium+olodaterol fixed dose combination (Tio+Olo FDC) assessed in parallel with the PMS of Tio+Olo FDC Respimat, BI trial number 1237.34
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Nippon Boehringer Ingelheim
- 24 Aug 2020 Status changed from active, no longer recruiting to completed.
- 14 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2017 New trial record